ReviewPharmaceutical research2007
Particle engineering for pulmonary drug delivery.
Review in Pharmaceutical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed.
- Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2.Drug delivery and translational research · 2026Article
- Drug delivery system of curcumin to the lungs based on poly(3-alloxyloxy-1,2-propylene succinate)-sebacic acid copolymers.Journal of pharmaceutical analysis · 2026Article
- CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.Pharmaceutics · 2026Article
- The Application of Machine Learning in the Development of Co-Amorphous Dry Powder Inhalation.AAPS PharmSciTech · 2026Article
- Machine Learning-Guided Development of Anti-Tuberculosis Dry Powder for Inhalation Prepared by Co-Spray Drying.Pharmaceutics · 2026Article
- Recent Developments in Pharmaceutical Spray Drying: Modeling, Process Optimization, and Emerging Trends with Machine Learning.Pharmaceutics · 2025Review
- From Bacterial Extract to Breakthrough Therapy:Pharmaceutics · 2025Article
- Coaxial Electrospray of Nanodrug-Loaded Porous Polylactic Acid/Poly(Ethylene Oxide) Core-Shell Microparticles for Intrapulmonary Drug Delivery.Journal of biomedical materials research. Part A · 2025Article
- Article
- Recent strategies for enhanced delivery of mRNA to the lungs.Nanomedicine (London, England) · 2025Review
- Advanced Manufacturing Methods for High-Dose Inhalable Powders.Pharmaceutics · 2025Review
- Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens.Viruses · 2025Review
- Optimization of Carrier-Based Dry Powder Inhaler Performance: A Review.Pharmaceutics · 2025Review
- Encapsulation of Nanocrystals in Mannitol-Based Inhalable Microparticles via Spray-Drying: A Promising Strategy for Lung Delivery of Curcumin.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Nebulization andMolecular pharmaceutics · 2024Article
- Using Dry Dispersion Laser Diffraction to Assess Dispersibility in Spheronized Agglomerate Formulations.AAPS PharmSciTech · 2024Article
- Imaging and Non-imaging Analytical Techniques Used for Drug Nanosizing and their Patents: An Overview.Recent patents on nanotechnology · 2024Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapidly growing popularity and sophistication of inhalation therapy, there is an increasing demand for tailor-made inhalable drug particles capable of affording the most efficient delivery to the lungs and the most optimal therapeutic outcomes. To cope with this formulation demand, a wide variety of novel particle technologies have emerged over the past decade. The present review is intended to provide a critical account of the current goals and technologies of particle engineering for the development of pulmonary drug delivery systems. These technologies cover traditional micronization and powder blending, controlled solvent crystallization, spray drying, spray freeze drying, particle formation from liquid dispersion systems, supercritical fluid processing and particle coating. The merits and limitations of these technologies are discussed with reference to their applications to specific drug and/or excipient materials. The regulatory requirements applicable to particulate inhalation products are also reviewed briefly.
Indexed as
Identifiers
17245651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.